Antibody discovery begins with the highest-quality antigen and advanced immunization strategies

Native-conformation antigen for high-quality antibodies

When you want to discover a high-quality therapeutic antibody, it’s essential to begin with the best antigen possible. That means full-length antigens with native structure at high concentration in a highly immunogenic format.

Immunization is the best approach for generating the most affinity matured, developable MAbs . To build the best foundation for discovery, we carefully evaluate each target and design an immunization and selection strategy that offers the best chance of isolating MAbs against the right epitope. This attention to detail often enables us to generate antibodies with picomolar affinity, even against difficult targets.

Whether your target is a highly conserved membrane protein or something less challenging, our immunization protocols always include native-conformation antigens for the best success.

Lipoparticle assembly and budding. A protein core moves from inside the cell; it buds off, carrying with it a surrounding lipid bilayer covered in membrane proteins.

Our proprietary Lipoparticles are an important part of our immunization strategy for membrane proteins.

Optimized for membrane proteins: Lipoparticles + mRNA

We routinely discover MAbs against the most challenging targets, including GPCRs and ion channels. A big part of that success is due to an advanced immunization protocol that combines Lipoparticles, nucleic acids, and proprietary adjuvants. But even before the immunization step, we apply our deep expertise in protein engineering to avoid pitfalls such as low expression and protein toxicity.

Icon: a hammer and a wrench

Antigen Optimization

Low expression or poor protein trafficking can often delay or derail other antibody discovery projects. Our scientists apply their 20+ years of experience in protein engineering to identify and troubleshoot potential issues before they are problems. We design and validate optimal high-concentration antigens for each project.
Icon: a Lipoparticle with embedded membrane proteins

Lipoparticle Experts

We invented Lipoparticles as the best antigen for delivering MAbs against challenging membrane proteins. Lipoparticles are virus-like particles (VLPs) that present membrane proteins in their native conformation—without solubilization or disruption by detergents—and in a highly immunogenic format. Because Lipoparticles concentrate proteins to a level 10-100x higher (~50-200 pmol/mg) than cells can produce, they elicit a robust, focused immune response. We use them for immunization, and then again for screening and biosensor binding characterization studies.
Icon: a segment of DNA and a segment of RNA

mRNA Immunization

Our scientists pioneered the use of nucleic acid immunization for antibody discovery long before it became popular. Even before the COVID-19 pandemic, we used mRNA immunization to produce superior results to DNA and a more complete and targeted immune response than protein alone. This approach is especially helpful for hitting challenging epitopes that can benefit from large, diverse immune libraries.
While we have refined our process to work with challenging membrane protein targets, we can discover therapeutic antibodies against all kinds of protein targets.

Eliciting robust immune responses, even for the most difficult targets

Schematics of easy, very difficult, and almost impossible targets, and their respective immunization responses. Targets are SARS-CoV-2 spike (easy), a GPCR (very difficult) and an ion channel (almost impossible). Graphs compare pre- and post-immunization bleeds. Following an mRNA plus Lipoparticle immunization, each target produced a robust response.

Immune responses from three of our antibody discovery projects. Our antigen and immunization strategies have delivered robust immune responses for nearly every target encountered to date .


Case Studies

MFSD2A | Transporter

MFSD2A antibody
Learn how the MPS Antibody Discovery Platform was leveraged to deliver an MFSD2A antibody to researchers at Harvard and Stanford. The antibody was featured in Nature for its role in deciphering the structure of MFSD2A.

SLC2A4 | Transporter

isolate state-specific antibodies against SLC2A4
Learn how the research team at Integral Molecular used Lipoparticles in conjunction with the MPS Antibody Discovery Platform to isolate state-specific antibodies against SLC2A4.

Contact Us

Ready To Get Started?

Contact us to discuss licensing therapeutic assets or initiating a discovery partnership.

Or call (215) 966-6061